Xi Chen

US Patent:

6740058, May 25, 2004

Filed:

Jun 8, 2001

Appl. No.:

09/877714

Inventors:

Amit Lal - Madison WI
Xi Chen - Madison WI

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61M 3100

US Classification:

604 65, 604 67

Abstract:

A surgical tool with a rigid body including a needle portion for entering tissue includes a fluid flow channel formed therethrough. A sensor is integrally formed on the tool to detect changing conditions (pressure and/or flow) in the channel. The sensor signal may be used to provide feedback control of pumping of fluid through the channel. The tool may be a micromachined silicon tool with the sensor integrally formed thereon from a silicon nitrate membrane and polysilicon resistors. The tool may be an ultrasonically activated cutting tool, which may be bonded to a package at a node thereof.

US Patent:

8163281, Apr 24, 2012

Filed:

Mar 3, 2010

Appl. No.:

12/716842

Inventors:

Yang Liu - Ann Arbor MI, US
Pan Zheng - Ann Arbor MI, US
Xincheng Zheng - Ann Arbor MI, US
Xi Chen - Woodland CA, US
Steve Kunkel - Ann Arbor MI, US

Assignee:

The Regents Of The University Of Michigan - Ann Arbor MI

International Classification:

A61K 39/395
A61K 39/00
A61K 38/16

US Classification:

4241301, 4241431, 4241841, 4241851, 514 212

Abstract:

The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.

US Patent:

20110004575, Jan 6, 2011

Filed:

Jun 9, 2010

Appl. No.:

12/796934

Inventors:

Lei Yang - Sunnydale CA, US
Robert P. Dick - Chelsea MI, US
Xi Chen - San Jose CA, US
Gokhan Memik - Evanston IL, US
Peter A. Dinda - Evanston IL, US
Alex Shye - Evanston IL, US
Berkin Ozisikyilmaz - Chicago IL, US
Arindam Mallik - Leuven, BE
Alok Choudhary - Chicago IL, US

International Classification:

G06F 15/18
G06F 1/32
G06F 1/26

US Classification:

706 12, 713320, 713300

Abstract:

Systems and methods for controlling power consumption in a computer system are disclosed. The computer system may be trained, for example, to determine relationship information between user satisfaction and discrete frequencies at which a processor of the computer system runs. The determined relationship can distinguish between different users and different interactive applications. A frequency may be selected from the discrete frequencies at which the processor of the computer system runs based on the determined relationship information for a particular user and a particular interactive application running on the processor of the computer system. The processor may be adapted to run at the selected frequency.

US Patent:

20120201819, Aug 9, 2012

Filed:

Mar 21, 2012

Appl. No.:

13/426392

Inventors:

Yang LIU - Ann Arbor MI, US
Pan ZHENG - Ann Arbor MI, US
Xi CHEN - Woodland CA, US
Steve KUNKEL - Ann Arbor MI, US
Xincheng ZHENG - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 39/395
A61K 31/7008
A61P 29/00
A61K 31/715

US Classification:

4241341, 4241731, 514 54, 514 23

Abstract:

The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.